#PayTmIPO – Long Thread:
There is a new game in town. The rules are “well laid out” by VCs – Report just 3 yr financials, blame flat sales since 2019 on covid, pick consultants to project fancy story, price IPO at 45 times sales, create scarcity of “limited offer” of 12% shares”
They say “a fool & his money will always be parted”.
But who rewards mediocrity? Well, enter #PaytmIPO. If Infosys & TCS were a bet on excellence, Paytm is a bet on mediocrity. We’ll see how.
But there is a catch here – Paytm seems to have got the last funding in 2019 at $ 16 Bn valuation. On that, the current pricing at $ 20 Bn seems fair, isn’t it?
Something tells me that the IPO was planned for 2020. But then Covid stuck in March 2020. No IPO happens in a bear market. Oops!
If Paytm doubles from here, it will be bigger than Axis bank & close to Kotak bank.“Super app” bigger than these banks?
Then there is ticketing biz, again trying to compete with the biggies already established in ticketing. We see new segments tried & folded without significant leadership
While industry is worried with too many stocks trading accounts, Paytm has barely started.What leadership execution do we value here?
Look at related party tranx disclosed in DRHP: Paytm pays Rs ~900 Cr revenue to its payment bank, which is owned 51% by promotor VSS. Hmm…okay!
No wonder the small bank & insurance licenses are lying with RBI & IRDA for over a year. Post IPO, “Ant fin” stake will fall <25% but is that good to inspire trust?
330 Mn “users” means 33 Cr people have tried Paytm at some point but haven’t adopted it
Since UPI dominance increased, Paytm is forced to reduce “take rate” it charges merchants (0.64%). Paytm revenues are falling despite rising spends!
More from Ipo
You May Also Like
Moderna CEO Stephane Bancel was previously CEO of bioMerieux in France from 07-10.
Alain Merieux, who owns bioMerieux, was instrumental in the creation of the Wuhan Institute of Virology P4 Lab.
The same people who helped create the virus, also helped to create the vaccines...
Moderna partnered with French Pasteur Institute in 2015 to develop mRNA vaccine technology.
Pasteur Institute partnered with the Wuhan P4 Laboratory in 2017 along with the Merieux Foundation to study emerging viruses...
https://t.co/yFsHwrNYaK
https://t.co/9M5lydBKhM
Nobel prize winning scientist Luc Montagnier asserts that Sars-Cov-2 is man-made and originated from the Wuhan Institute of Virology.
Montagnier did extensive work with the Pasteur Institute in France which was partnered with the Wuhan P4.
Merieux Foundation & the Chinese government have worked together since 1965, and partnered to study emerging pathogens in Africa in 2015.
Their research included "PATHOGENS CARRIED BY BATS" that provoke respiratory diseases.
🚨🚨🚨
https://t.co/gVwpT0ssqI
Alain Merieux, who owns bioMerieux, was instrumental in the creation of the Wuhan Institute of Virology P4 Lab.
The same people who helped create the virus, also helped to create the vaccines...
Moderna partnered with French Pasteur Institute in 2015 to develop mRNA vaccine technology.
Pasteur Institute partnered with the Wuhan P4 Laboratory in 2017 along with the Merieux Foundation to study emerging viruses...
https://t.co/yFsHwrNYaK
https://t.co/9M5lydBKhM
Nobel prize winning scientist Luc Montagnier asserts that Sars-Cov-2 is man-made and originated from the Wuhan Institute of Virology.
Montagnier did extensive work with the Pasteur Institute in France which was partnered with the Wuhan P4.
Merieux Foundation & the Chinese government have worked together since 1965, and partnered to study emerging pathogens in Africa in 2015.
Their research included "PATHOGENS CARRIED BY BATS" that provoke respiratory diseases.
🚨🚨🚨
https://t.co/gVwpT0ssqI